Publication

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study

Voorham, J., Baldi, S., Santoro, L., Kerkhof, M., Contoli, M., Fabbri, L. M., Kerstjens, H. A. M., Luis López-Campos, J., Roche, N., Singh, D., Vogelmeier, C. F. & Price, D. B., 2020, In : International Journal of Chronic Obstructive Pulmonary Disease. 15, p. 2739-2750 12 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Jaco Voorham
  • Simonetta Baldi
  • Luigi Santoro
  • Marjan Kerkhof
  • Marco Contoli
  • Leonardo M Fabbri
  • Huib A M Kerstjens
  • Jose Luis López-Campos
  • Nicolas Roche
  • Dave Singh
  • Claus F Vogelmeier
  • David B Price

Purpose: This study aimed to evaluate the non-inferiority of initiating extrafine beclometasone dipropionate/formoterol fumarate (BDP/FF) versus double bronchodilation (long-acting beta-agonists [LABA]/long-acting muscarinic antagonists [LAMA]) among patients with a history of chronic obstructive pulmonary disease (COPD) exacerbations.

Patients and Methods: A historical cohort study was conducted using data from the UK's Optimum Patient Care Research Database. Patients with COPD ≥40 years at diagnosis were included if they initiated extrafine BDP/FF or any LABA/LAMA double therapy as a step-up from no maintenance therapy or monotherapy with inhaled corticosteroids (ICS), LAMA, or LABA and a history of ≥2 moderate/severe exacerbations in the previous two years. The primary outcome was exacerbation rate from therapy initiation until a relevant therapy change or end of follow-up. Secondary outcomes included rate of acute respiratory events, acute oral corticosteroids (OCS) courses, and antibiotic prescriptions with lower respiratory indication, modified Medical Research Council score (mMRC) ≥2, and time to first pneumonia diagnosis. The non-inferiority boundary was set at a relative difference of 15% on the ratio scale. Five potential treatment effect modifiers were investigated.

Results: A total of 1735 patients initiated extrafine BDP/FF and 2450 patients initiated LABA/LAMA. The mean age was 70 years, 51% were male, 41% current smokers, and 85% had FEV1 <80% predicted. Extrafine BDP/FF showed non-inferiority to LABA/LAMA for rate of exacerbations (incidence rate ratio [IRR] = 1.01 [95% CI 0.94-1.09]), acute respiratory events (IRR = 0.98 [0.92-1.04]), acute OCS courses (IRR = 1.01 [0.91-1.11]), and antibiotic prescriptions (IRR = 0.99 [0.90-1.09]), but not for mMRC (OR = 0.93 [0.69-1.27]) or risk of pneumonia (HR = 0.50 [0.14-1.73]). None of the a priori defined effect modifier candidates affected the comparative effectiveness.

Conclusion: This study found that stepping up to extrafine BDP/FF from no maintenance or monotherapy was not inferior to stepping up to double bronchodilation therapy in patients with a history of exacerbations.

Original languageEnglish
Pages (from-to)2739-2750
Number of pages12
JournalInternational Journal of Chronic Obstructive Pulmonary Disease
Volume15
Publication statusPublished - 2020

Download statistics

No data available

ID: 144609425